Doxorubicin-conjugated PEGylated dendrimers show similar tumoricidal activity but lower systemic toxicity when compared to PEGylated liposome and solution formulations in mouse and rat tumor models

Molecular Pharmaceutics

Volumn 9, Issue 3, 2012, Pages 422-432

  Kaminskas, Lisa M ^a   McLeod, Victoria M ^a   Kelly, Brian D ^b   Cullinane, Carleen ^c,d   Sberna, Gian ^b   Williamson, Mark ^e   Boyd, Ben J ^a   Owen, David J ^b   Porter, Christopher J H ^a  

^a MONASH UNIVERSITY   (Australia)

^b Starpharma Holdings Limited   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e GRIBBLES PATHOLOGY   (Australia)

Author keywords

dendrimer; doxorubicin; liposome; PEGylation; tumor

Indexed keywords

DENDRIMER; DOXORUBICIN; LIPOSOME; PEGYLATED DENDRIMER; PEGYLATED POLYLYSINE DENDRIMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUTION; FEMALE; HAND FOOT SYNDROME; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; DENDRIMERS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; POLYETHYLENE GLYCOLS; RATS; RATS, NUDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84858060982     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp200522d     Document Type: Article

References (38)

1. Thanou, M.; Duncan, R. Polymer-protein and polymer-drug conjugates in cancer therapy Curr. Opin. Invest. Drugs 2003, 4, 701-9 (Pubitemid 36916711)
2. Wang, M.; Thanou, M. Targeting nanoparticles to cancer Pharmacol. Res. 2010, 62, 90-9
3. Chau, Y.; Padera, R. F.; Dang, N. M.; Langer, R. Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models Int. J. Cancer 2006, 118, 1519-26
4. Tsukioka, Y.; Matsumura, Y.; Hamaguchi, T.; Koike, H.; Moriyasu, F.; Kakizoe, T. Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil) Jpn. J. Cancer Res. 2002, 93, 1145-53 (Pubitemid 35314960)
5. Wang, J.; Sui, M.; Fan, W. Nanoparticles for tumor targeted therapies and their pharmacokinetics Curr. Drug Metab. 2010, 11, 129-41
6. Fossa, S. D.; Vaage, S.; Letocha, H.; Iversen, J.; Risberg, T.; Johannessen, D. C.; Paus, E.; Smedsrud, T. Liposomal doxorubicin (Caelyx) in symptomatic androgen-independent prostate cancer (AIPC): delayed response and flare phenomenon should be considered Scand. J. Urol. Nephrol. 2002, 36, 34-9 (Pubitemid 34225300)
7. D'Agostino, G.; Ferrandina, G.; Ludovisi, M.; Testa, A.; Lorusso, D.; Gbaguidi, N.; Breda, E.; Mancuso, S.; Scambia, G. Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer Br. J. Cancer 2003, 89, 1180-4 (Pubitemid 37363399)
8. Kaminskas, L. M.; Kelly, B. D.; McLeod, V. M.; Boyd, B. J.; Krippner, G. Y.; Williams, E. D.; Porter, C. J. H. Pharmacokinetics and tumor disposition of PEGylated, methotrexate conjugated poly-l-lysine dendrimers Mol. Pharmaceutics 2009, 6, 1190-204
9. Lammers, T.; Storm, G. Nanomedicine formulations for combination therapies Nano Rev. 2010, 1, 5705
10. Lammers, T.; Hennink, W. E.; Storm, G. Tumour-targeted nanomedicines: principles and practice Br. J. Cancer 2008, 99, 392-7
11. Zhang, W.; Shi, Y.; Chen, Y.; Yu, S.; Hao, J.; Luo, J.; Sha, X.; Fang, X. Enhanced antitumor efficacy by paclitaxel-loaded pluronic P123/F127 mixed micelles against non-small cell lung cancer based on passive tumor targeting and modulation of drug resistance Eur. J. Pharm. Biopharm. 2010, 75, 341-53
12. Jabr-Milane, L. S.; van Vlerken, L. E.; Yadav, S.; Amiji, M. M. Multi-functional nanocarriers to overcome tumor drug resistance Cancer Treat. Rev. 2008, 34, 592-602
13. Chen, Y.; Bathula, S. R.; Li, J.; Huang, L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer J. Biol. Chem. 2010, 285, 22639-50
14. Vail, D. M.; Amantea, M. A.; Colbern, G. T.; Martin, F. J.; Hilger, R. A.; Working, P. K. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies Semin. Oncol. 2004, 31, 16-35 (Pubitemid 40023240)
15. Dhanikula, R. S.; Argaw, A.; Bouchard, J. F.; Hildgen, P. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability Mol. Pharmaceutics 2008, 5, 105-16 (Pubitemid 351300040)
16. Smith, L. A.; Cornelius, V. R.; Plummer, C. J.; Levitt, G.; Verrill, M.; Canney, P.; Jones, A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials BMC Cancer 2010, 10, 337
17. Stavridi, F.; Palmieri, C. Efficacy and toxicity of nonpegylated liposomal doxorubicin in breast cancer Expert Rev. Anticancer Ther. 2008, 8, 1859-69
18. Lorusso, D.; Di Stefano, A.; Carone, V.; Fagotti, A.; Pisconti, S.; Scambia, G. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) Ann. Oncol. 2007, 18, 1159-64 (Pubitemid 47244360)
19. Matsumura, Y.; Hamaguchi, T.; Ura, T.; Muro, K.; Yamada, Y.; Shimada, Y.; Shirao, K.; Okusaka, T.; Ueno, H.; Ikeda, M.; Watanabe, N. Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin Br. J. Cancer 2004, 91, 1775-81 (Pubitemid 39664964)
20. Nakanishi, T.; Fukushima, S.; Okamoto, K.; Suzuki, M.; Matsumura, Y.; Yokoyama, M.; Okano, T.; Sakurai, Y.; Kataoka, K. Development of the polymer micelle carrier system for doxorubicin J. Controlled Release 2001, 74, 295-302 (Pubitemid 32727635)
21. Kaminskas, L. M.; Kelly, B. D.; McLeod, V. M.; Sberna, G.; Boyd, B. J.; Owen, D. J.; Porter, C. J. H. Capping methotrexate alpha-carboxyl groups enhances systemic exposure and retains the cytotoxicity of drug conjugated PEGylated polylysine dendrimers Mol. Pharmaceutics 2011, 8, 338-49
22. Chau, Y.; Dang, N. M.; Tan, F. E.; Langer, R. Investigation of targeting mechanism of new dextran-peptide-methotrexate conjugates using biodistribution study in matrix-metalloproteinase-overexpressing tumor xenograft model J. Pharm. Sci. 2006, 95, 542-51
23. Erez, R.; Segal, E.; Miller, K.; Satchi-Fainaro, R.; Shabat, D. Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel Bioorg. Med. Chem. 2009, 17, 4327-35
24. Calderon, M.; Graeser, R.; Kratz, F.; Haag, R. Development of enzymatically cleavable prodrugs derived from dendritic polyglycerol Bioorg. Med. Chem. Lett. 2009, 19, 3725-8
25. Kaminskas, L. M.; McLeod, V. M.; Kelly, B. D.; Sberna, G.; Boyd, B. J.; Williamson, M.; Owen, D. J.; Porter, C. J. H. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems Nanomedicine (Philadelphia, PA, U.S.) 2012, 8, 103-11
26. Kaminskas, L. M.; Kelly, B. D.; McLeod, V. M.; Sberna, G.; Owen, D. J.; Boyd, B. J.; Porter, C. J. H. Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker J. Controlled Release 2011, 152, 241-8
27. Kaminskas, L. M.; Boyd, B. J.; Porter, C. J. H. Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties Nanomedicine (U.K.) 2011, 6, 1063-84
28. England, J. D.; Asbury, A. K.; Rhee, E. K.; Sumner, A. J. Lethal retrograde axoplasmic transport of doxorubicin (adriamycin) to motor neurons. A toxic motor neuronopathy Brain 1988, 111 (Pt 4) 915-26
29. Kondo, A.; Ohnishi, A.; Nagara, H.; Tateishi, J. Neurotoxicity in primary sensory neurons of adriamycin administered through retrograde axoplasmic transport in rats Neuropathol. Appl. Neurobiol. 1987, 13, 177-92 (Pubitemid 17114156)
30. Dalakas, M. C. Chronic idiopathic ataxic neuropathy Ann. Neurol. 1986, 19, 545-54 (Pubitemid 16085188)
31. Sterman, A. B.; Schaumburg, H. H.; Asbury, A. K. The acute sensory neuronopathy syndrome: a distinct clinical entity Ann. Neurol. 1980, 7, 354-8 (Pubitemid 10112831)
32. Lorusso, V.; Manzione, L.; Silvestris, N. Role of liposomal anthracyclines in breast cancer Ann. Oncol. 2007, 18, 70-3
33. Harris, L.; Batist, G.; Belt, R.; Rovira, D.; Navari, R.; Azarnia, N.; Welles, L.; Winer, E.; Group, T. D. S. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicentre trial as first-line therapy of metastatic breast cancer Cancer 2002, 94, 25-36 (Pubitemid 34049039)
34. Northfelt, D. W.; Martin, F. J.; Working, P.; Volberding, P. A.; Russell, J.; Newman, M.; Amantea, M. A.; Kaplan, L. D. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma J. Clin. Pharmacol. 1996, 36, 55-63 (Pubitemid 26058811)
35. Lee, C.; Gillies, E.; Fox, M.; Guillaudeu, S.; Frechet, L.; Dy, E.; Szoka, F. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 16649-54 (Pubitemid 44737307)
36. Vail, D. M.; Kravis, L. D.; Cooley, A. J.; Chun, R.; MacEwen, E. G. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors Cancer Chemother. Pharmacol. 1997, 39, 410-6 (Pubitemid 27078125)
37. Krishna, R.; Mayer, L. D. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors Cancer Res. 1997, 57, 5246-53 (Pubitemid 27516357)
38. Sadava, D.; Coleman, A.; Kane, S. E. Liposomal daunorubicin overcomes drug resistance in human breast, ovarian and lung carcinoma cells J Liposome Res. 2002, 12, 301-9 (Pubitemid 36008393)